New data, released by the UK BioIndustry Association (BIA) and Informa Pharma Intelligence, has revealed that the venture capital funding and secondary offerings in the biotech sector are on track to beat last year’s figures, maintaining the UK’s lead within Europe.
Funding
Topline data from the ‘Biotech Financing Update, January–June 2017’ demonstrate that UK biotech continues to dominate venture capital funding in Europe and it is also ranked third in a global setting, raising £361.4 million. Other key outcomes show that at the halfway point for this year, seed, second round and later funding are all on track to meet or surpass the figures for 2016; secondary public funding rounds are on track to meet or surpass last year’s figures with £261 million raised in 16 offerings across AIM and Nasdaq; and the emergence of Biopharma Credit could be a novel source of debt finance for UK life science.